1. Study of Lipid Profile in Obese and Non-obese Students in Acharya Nagarjuna University K Suneetha
Obesity is an excessive accumulation of energy in the form of body fat which impairs health. It is associated with an increased risk of developing various non-communicable diseases, including hypertension, coronary heart disease, diabetes, stroke and some forms of cancer. Obesity has been found to be associated with changes in levels of serum triglycerides and it may differ with age, sex, weight, height, BMI (Body Mass Index) and life style groups. This study aims at measuring and correlating values of Body mass index (BMI) with serum lipids and prevalence of dyslipidemia according to level of BMI in students of science college, Acharya nagarjuna university,Guntur(district), A.P
2. Effect of Ethanolic Extract of Leaves of Boerhavia diffusa on Carbohydrate Metabolising Enzymes, Renal and Hepatic Markers in Streptozotocin Induced Diabetic Rats C.C.S. Vasundhara , S. Gayathri Devi
The present study was formulated to evaluate the effect of Boerhavia diffusa by using in vivo methods in normal and streptozotocin (STZ) induced diabetic rats. Diabetes mellitus was induced by single intraperitoneal injection of STZ (60 mg/kg body weight) in male Wistar rats. Various parameters such as carbohydrate metabolizing enzymes, renal and hepatic markers were studied in the normal and diabetes induced rat. The ethanolic extract of leaves of Boerhavia diffusa (ELBD) at a dose of 500 mg/kg body weight and glibenclamide, a standard oral hypoglycemic drug at a dose of 10 mg/kg body weight were administered orally to the diabetic induced groups for 45 days. The diabetic induced groups treated with the ELBD restored the elevated levels of renal and hepatic markers to normal levels. It also altered the activities of carbohydrate metabolizing enzymes to near normal. Thus, from the present study it can be concluded that the ethanolic extract of leaves of Boerhavia diffusa possess a favourable antidiabetic effect.
Simultaneous Determination of Losartan Potassium in Pharmaceutical Products by Reversed Phase High Performance Liquid Chromatography Raju Chandra, Abhishek Saini, Ashwani Sanghi, Ganesh Pandey, Deepak Kumar
Objective: Method validation is an important aspect for the determination of pharmaceutical products. A well validated method play an important role in the control of quality of the products. So this purpose the proposed study have been done regarding develop a validated method for losartan potassium. Methods: A reversed phase high performance liquid chromatographic method used on isocratic mode. Results: The chromatographic separation of losartan potassium was obtained using a C18 column by isocratic elusion at the 250C column temperature. The green solvent (methanol and water, 30:70 v/v) was used as a mobile phase. The analysis was performed at the flow rate 1.0 ml/min. A well defined peak was detected at 273 nm. The retention time of acive engredients losartan potassium was obtained in 7 min. The limit of detection and limit of quantification was calculated 0.03 and 0.09 µg/ml, respectively. A Good results was obtained with respect to linearity R2=0.998. The mean recoveries in inter-day and intra-day were calculated 98.85 % and 99.4 % with CV value 1.38 and 2.24 respectively. Conclusion: The method was validated according to ICH guidelines. This method is very efficient for the analysis of losartan potassium at 25 0C.
4. Investigation and Management of Glycogen Storage Disease Type VI Amitha Mary John, Neelima Venugopal, K Krishnaveni, R Shanmuga Sundaram, R Sambathkumar
Glycogen storage disease (GSD) type VI or Hers disease is a rare form of GSD which is caused by hepatic glycogen phosphorylase deficiency encoded by the glycogen phosphorylase L (PYGL) gene and inherited by autosomal recessive inheritance. PYGL gene mutations prevent liver glycogen phosphorylase (LGP) from breaking down glycogen effectively. Hers disease is a clinically and genetically heterogeneous group of disorders characterized by hepatomegaly, hypoglycemia, growth retardation and hyperlipidemia. The diagnosis of hepatic GSDs requires a proper and specific clinical history and examination. Determination of the mutation in the PYGL gene on chromosome number 14 provides a basis for the diagnostic test of this disease. Therapy for this disease needs very careful dietetic management with prospective surveillance for complications. Treatment with corn starch and a high protein diet is recommended in an effort to improve the clinical features of this disease.